Itolizumab

Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon[1] and the Center of Molecular Immunology (CIM), Havana.[2]

Itolizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCD6
Clinical data
Trade namesAlzumab
ATC code
  • none
Legal status
Legal status
  • Approved in India
Identifiers
CAS Number
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

Mechanism of action

It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.[3]

Clinical trials

A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.[4]

Applications

Biocon received marketing authorization for the drug from the Drugs Controller General of India (DCGI) in January 2013 and marketing within India commenced in August 2013.[1][5]

In July 2020, Biocon received authorization in India for its use in the treatment of COVID-19.[6]

References
  1. Jayaramun K (December 2013). "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. 31 (12). United Kingdom. pp. 1062–3.
  2. "India prepares to test Itolizumab, the drug credited for lowering Covid mortality in Cuba". May 30, 2020.
  3. "Biocon Receives Marketing Authorization for its Novel Biologic Itolizumab for Psoriasis" (PDF). Biocon Limited. 8 January 2013.
  4. Urs A. "Biocon's test shows positive results for Itolizumab". @businessline.
  5. "Biocon's psoriasis drug, Itolizumab receives DCGI marketing authorization". Pharmabiz.com. India: Saffron Media. January 8, 2013.
  6. "Biocon's Itolizumab approved for COVID-19 treatment: All you need to know". The Economic Times. Retrieved 2020-07-14.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.